title: Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
authors.affiliation: Department of Endocrinology (S.K.), Consultant (Endocrinology and Metabolism), Bharti Hospital, Kunjpura Road, Karnal 132001, Haryana, India; and Department of Endocrinology and Metabolism (Y.G.), All India Institute of Medical Sciences, New Delhi, 110029, India E-mail: brideknl@gmail.com .
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
authors.affiliation: Department of Endocrinology (S.K.), Consultant (Endocrinology and Metabolism), Bharti Hospital, Kunjpura Road, Karnal 132001, Haryana, India; and Department of Endocrinology and Metabolism (Y.G.), All India Institute of Medical Sciences, New Delhi, 110029, India E-mail: brideknl@gmail.com .
authors.forename: Yashdeep
authors.initials: Y
authors.lastname: Gupta
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005934:Glucagon / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D005934:Glucagon